Palisade Bio presented clinical and mechanistic data supporting the Phase 2 development of PALI-2108, an oral PDE4 inhibitor prodrug, for ulcerative colitis and Crohn’s disease at ACG 2026. Early studies showed clinical response, target engagement, and reduced inflammation in small patient groups, with favorable tolerability and sustained drug exposure. The data also suggest potential for precision medicine approaches and support ongoing larger Phase 2 trials. Two presentations received prestigious ACG Presidential Poster Awards, highlighting the scientific merit of the findings.
Palisade Bio's clinical and mechanistic data presentations at ACG 2026 support Phase 2 trials for PALI-2108 in ulcerative colitis and Crohn’s disease. For readers following the health sector, here is Pluang's market snapshot as of Oct 12, 2026 18:51 WIB: out of 128 priced US health stocks, 64 rose and 43 fell. Notable movers include DNA (Ginkgo Bioworks Holdings Inc) at USD 12.79 with a -1.62% change, ADMA (ADMA Biologics Inc) at USD 10.20 with -1.54%, and AXGN (Axogen Inc) at USD 36.66 with +1.47%, with typical hold times ranging from 7 to 18 days on Pluang.
Alignment Health Plan introduced Central Health Harmony, a new Medicare Advantage plan starting January 1, 2027, targeting Asian American seniors in Los Angeles and Orange counties. The plan offers access to over 600 physicians who speak Chinese, Kor...
NVIDIA and Cisco have introduced Ultra-Dense Small Form Factor Pluggable (USFP), a new optical module supporting 400Gb/s per lane, enabling up to 12.8Tb/s capacity for AI data centers. This technology doubles bandwidth per lane and increases power ef...
Hasbro announced the fourth annual Women Innovators of Play Design Challenge, accepting submissions from October 15 to November 20, 2026. The program now includes year-round in-person networking events alongside the design competition, aiming to conn...
Micas Networks introduced three new 102.4 Tbps open Ethernet switch platforms based on Broadcom Tomahawk 6 technology, designed to enhance AI factory networks. The portfolio includes air-cooled 800G, liquid-cooled 1.6T, and co-packaged optics (CPO) s...
Ferrari N.V. has repurchased 43,000 of its common shares on Euronext Milan as part of the third tranche of its multi-year €3.5 billion share buyback program announced in 2025. The recent purchases, totaling nearly €14.8 million, are part of a broader...
